Navigation Links
Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders
Date:11/23/2009

CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ --

Dear Isis Supporters and Shareholders,

I would like to start by thanking you for your continuing support of Isis. We believe we are at one of the most successful moments in our history. We are truly at the end of the beginning of creating a unique company with a novel drug discovery platform, which we believe addresses many of the issues haunting the pharmaceutical industry.

Our progress is predicated largely upon the success of our flagship drug, mipomersen. Mipomersen continues to perform well and progress toward commercialization. Isis, our investigators and members of the medical community are very encouraged by the results that were presented at the AHA last week. To get a sense of their support of the drug, I would encourage you to listen to the replay of the mipomersen investigator panel presentation that was conducted during AHA last week. I think you will hear not only their enthusiasm for the drug but their hope that mipomersen will provide a new treatment alternative for their patients at very high risk of cardiovascular disease.

We are disappointed with the reaction on Wall Street to what we believe is very positive news. We believe mipomersen will continue to provide results that speak for themselves. Each success brings us closer to getting mipomersen to the market and making the drug available to patients in need.

Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve the productivity of the pharmaceutical industry. With 19 drugs in development, we have one of the largest and most diverse pipelines in our industry. We know that sick people depend on us. We continue to strive for excellence as we create drugs for the future. We also recognize that behind our successes is the support we receive from you. I would like to personally thank you for that.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
2. Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth Conference
3. Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
4. Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
5. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
6. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
7. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
8. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
9. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
10. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
11. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Dr Murray Grossan was interviewed for an article in ... October 2014 issue of Bottom Line Personal magazine, there will ... treating snoring, and in some cases Obstructive Sleep Apnea. ... adults snore occasionally, and about 25% do it all the ... the back of the throat tend to sag when you ...
(Date:8/21/2014)... 22, 2014 Benefiting from accelerated ... medical expenses, the Chinese orthopedic instrument market demand ... a CAGR of 19.2% during 2009-2013. Trauma products, ... segments of orthopedic instruments in China, of which ... share in 2013. , Being optimistic about bright ...
(Date:8/21/2014)... 2014 Strongly influenced by their ... when there are no consequences, researchers in Georgia ... , This could imply that humans are less ... others, researchers said. Their findings are published in ... sense of unfairness is affected by their self-interest, ...
(Date:8/21/2014)... August 21, 2014 Local agencies in ... larger discounts for specific protection plans, according to released ... consumers to quote life insurance from local agencies using ... local agents that appear inside of the national system ... method of price reviews this year. Adults who enter ...
(Date:8/21/2014)... 22, 2014 The “Proteomics Market ... Chromatography, Electrophoresis, Surface Plasmon Resonance, X-ray Crystallography) - ... 2018", analyzes and studies the major market drivers, ... and the Rest of the World (RoW) , ... through 415 pages and in-depth TOC on “Proteomics ...
Breaking Medicine News(10 mins):Health News:Dr Murray Grossan Explains how and why Singing Exercises Stop Snoring 2Health News:Dr Murray Grossan Explains how and why Singing Exercises Stop Snoring 3Health News:China Orthopedic Instrument Industry Report, 2014-2017 Now Available at ChinaMarketResearchReports.com 2Health News:China Orthopedic Instrument Industry Report, 2014-2017 Now Available at ChinaMarketResearchReports.com 3Health News:China Orthopedic Instrument Industry Report, 2014-2017 Now Available at ChinaMarketResearchReports.com 4Health News:Influenced by Self-Interest, Humans Less Concerned About Inequity To Others, Researchers Find 2Health News:Influenced by Self-Interest, Humans Less Concerned About Inequity To Others, Researchers Find 3Health News:Life Insurance from Local Agents Now Priced Nationally Through Complimentary Tool Online 2Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 5
... in births of autistic children have led to a fear ... towards an autistic epidemic. However a recent report, which was ... out that this is not true. The report points out ... autistic epidemic., ,The study had pointed out that recent ...
... size at birth, as a marker of an adverse ... // death from cardiovascular disease, according to the study ... obtained by studying 13830 individuals born between 1924 and ... causes of death between 1971 and 1998 was obtained ...
... Aptivus ( tipranavir ) , has been recently approved ... are to be given in combination with ritonavir for treatment ... for patients with advanced HIV disease, and provides a new ... of Aptivus in combination with ritonavir, has shown to be ...
... to varying degrees of energy loss during aerobic exercises and ... our bodies react to exercise programs is genetic in origin ... level of blood glucose in the body etc. ,According ... Washington University School of Medicine, exercise can help the scientists ...
... India ,German Remedies, a part of the Zydus group, has ... lymphocytic leukemia. Chronic Lymphocytic Leukemia (CLL) is a cancer of ... present has no cure. The disease is unknown in childhood, ... with increasing age. ,Fludarabine has emerged as one ...
... of the smokers reveals that the smokers may differ in ... to smoking. ,Researchers have found that the urge to ... according to the brain responses to the smoking habit. Researchers ... brain images of smokers in a bid to study the ...
Cached Medicine News:
(Date:8/21/2014)... FLORHAM PARK, N.J. , Aug. 21, 2014 ... specialty pharmacy group purchasing organization (GPO), is pleased ... (Aurora) to collaborate on a host of innovative ... will help Aurora deliver enhanced therapy management services ... Therapy Management (OTM) system. Aurora will ...
(Date:8/21/2014)... TORONTO , Aug. 21, 2014 /CNW/ - Bedrocan ... appointed three independent members to its Board of ... care experience of the company, a leading licensed ... . Internationally, Bedrocan has 13 years, experience ... patients in seven countries, including Canada. ...
(Date:8/21/2014)... 21, 2014   Auxilium Pharmaceuticals, Inc. ... company, today announced positive results from a randomized, ... (or CCH) for the treatment of edematous fibrosclerotic ... Phase 2a trial, all three doses of CCH ... an improvement in the appearance of cellulite as ...
Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: